Organogenesis

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Organogenesis and other ETFs, options, and stocks.

About ORGO

Organogenesis Holdings, Inc. is a regenerative medical company, which engages in the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical and sports medicine markets. The company was founded in 1985 and is headquartered in Canton, MA. 

CEO
Gary S. Gillheeney
CEOGary S. Gillheeney
Employees
869
Employees869
Headquarters
Canton, Massachusetts
HeadquartersCanton, Massachusetts
Founded
1985
Founded1985
Employees
869
Employees869

ORGO Key Statistics

Market cap
759.87M
Market cap759.87M
Price-Earnings ratio
-59.84
Price-Earnings ratio-59.84
Dividend yield
Dividend yield
Average volume
2.07M
Average volume2.07M
High today
$6.07
High today$6.07
Low today
$5.73
Low today$5.73
Open price
$5.78
Open price$5.78
Volume
500.79K
Volume500.79K
52 Week high
$7.08
52 Week high$7.08
52 Week low
$2.61
52 Week low$2.61

Stock Snapshot

The current Organogenesis(ORGO) stock price is $5.85, with a market capitalization of 759.87M. The stock trades at a price-to-earnings (P/E) ratio of -59.84.

On 2025-12-26, Organogenesis(ORGO) stock traded between a low of $5.73 and a high of $6.07. Shares are currently priced at $5.85, which is +2.1% above the low and -3.6% below the high.

The Organogenesis(ORGO)'s current trading volume is 500.79K, compared to an average daily volume of 2.07M.

In the last year, Organogenesis(ORGO) shares hit a 52-week high of $7.08 and a 52-week low of $2.61.

In the last year, Organogenesis(ORGO) shares hit a 52-week high of $7.08 and a 52-week low of $2.61.

ORGO News

TipRanks 2d
Organogenesis initiates rolling submission of BLA to FDA for ReNu

Organogenesis (ORGO) announced the initiation of a rolling submission of a Biologics License Application to the FDA for ReNu, a cryopreserved, amniotic suspensi...

TipRanks 3d
Organogenesis Nears Key Data Milestone With Phase 3 Knee Osteoarthritis Study

Organogenesis Holdings (ORGO) announced an update on their ongoing clinical study. Claim 70% Off TipRanks This Holiday Season Unlock hedge-fund level data and p...

People also own

Based on the portfolios of people who own ORGO. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.